On 29 October, Alzinova AB, a Swedish biopharma company developing treatments for Alzheimer’s disease (AD), announced the start of a new phase Ib clinical trial testing its ALZ-101 vaccine for AD. ALZ-801 is a vaccine that stimulates the production of antibodies against the neurotoxic amyloid-beta oligomers.
The new phase Ib trial is a placebo-controlled and double-blind study evaluating the tolerability and safety of ALZ-801 in people with early AD in Finland. The study will also analyse the immunological response to the vaccine after multiple doses, as well as a number of biomarkers associated with AD. The company intends to recruit 26 participants, who will receive four doses of either ALZ-101 or placebo over a 20-week treatment period. Top-line results are expected in the second half of 2023.
https://www.alzinova.com/investors/press-releases/press/?releaseID=DB98427790F4DD3A
